PBIO Pressure BioSciences Adding Daniel J. Shea as
Post# of 1354
(Total Views: 119)
Posted On: 09/25/2019 10:25:15 AM
PBIO Pressure BioSciences Adding Daniel J. Shea as Chief Financial Officer
Shea’s 30-Year Diverse Experience in Acquisitions, Capital Markets, SEC Reporting, and Leading Financial Organizations Bolsters PBI’s Strong Senior Management Team
South Easton, MA, Sept. 17, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Pressure BioSciences, Inc. (PBIO) (“PBI” or the “Company”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide life sciences industry, today announced that Mr. Daniel J. Shea has joined the Company as Sr. Vice President and Chief Financial Officer (“CFO”) effective Friday, September 13, 2019. In this key leadership position, Mr. Shea will be responsible for directing and overseeing all aspects of the Finance and Administration functions of the Company, including financial reporting and analysis; compliance with GAAP and applicable laws and rules for financial and tax reporting; forecasting and budgeting; primary liaison with the Company’s independent accounting firm; and leadership in the development of short and long-term financial objectives.
“It’s an exciting time to join Pressure BioSciences,” said Mr. Shea. “PBI’s unique platform technologies, worldwide customer base, growing revenue stream, and strong management team position the Company well to capitalize on substantial growth opportunities across the globe. I stand ready to support the Company’s commitment to high-quality financial reporting and internal control as it navigates through these opportunities in the coming years. I look forward to using my background and skills to facilitate the Company’s growth while we bring increased value to all shareholders.”
Mr. Shea, age 54, has over 30 years of experience in leading and advising financial organizations. Since January 2017, he has operated Woodcliff Advisors LLC, a CPA advisory firm providing counsel to boards, CFOs and senior management. Through Woodcliff, Mr. Shea personally filled CFO roles at public and private companies in the financial services and technology industries. From 1998 to 2016, he was a Senior Vice President at Affiliated Managers Group, Inc., a publicly traded asset management holding company with a long record of growth through acquisition. His core experience is in acquisitions, SEC reporting, internal controls, and the capital markets. Previously, he advised financial services firms at PricewaterhouseCoopers where his clients included asset managers, banks, private equity firms, mutual funds and leasing companies. Mr. Shea is a certified public accountant and earned his B.S. in Finance and Accounting from Boston College.
Mr. Richard T. Schumacher, President and CEO of PBI, added: “We are pleased to have someone with Dan’s experience and capabilities join PBI at such an important time in our corporate evolution. We believe all three of our patented technology business platforms have the potential for rapid growth over the next 12-18 months. To that end, we have given guidance that we believe total revenue in 2020 will be more than double total revenue of 2019. Such rapid growth will require reliable and supportive financial systems to be securely in place to facilitate smooth and timely financial reporting. It will also require a close and continued relationship with the capital markets. We are fortunate to have a seasoned financial professional like Dan join us at this most important time, to lead this financial transformation.”
Mr. Schumacher continued: “I will be transferring many responsibilities to Dan that have been on my plate as interim CFO. This welcomed transition will allow me to focus time on multiple opportunities that we believe offer great potential for commercial growth and increased financial security for PBI, including strategic partnerships, collaborations, acquisitions, and customer adoption/revenue acceleration programs. This is a very exciting time for stakeholders in PBI.”
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. (PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired, patented technology from BaroFold, Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., CBD Oil and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.
Shea’s 30-Year Diverse Experience in Acquisitions, Capital Markets, SEC Reporting, and Leading Financial Organizations Bolsters PBI’s Strong Senior Management Team
South Easton, MA, Sept. 17, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Pressure BioSciences, Inc. (PBIO) (“PBI” or the “Company”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide life sciences industry, today announced that Mr. Daniel J. Shea has joined the Company as Sr. Vice President and Chief Financial Officer (“CFO”) effective Friday, September 13, 2019. In this key leadership position, Mr. Shea will be responsible for directing and overseeing all aspects of the Finance and Administration functions of the Company, including financial reporting and analysis; compliance with GAAP and applicable laws and rules for financial and tax reporting; forecasting and budgeting; primary liaison with the Company’s independent accounting firm; and leadership in the development of short and long-term financial objectives.
“It’s an exciting time to join Pressure BioSciences,” said Mr. Shea. “PBI’s unique platform technologies, worldwide customer base, growing revenue stream, and strong management team position the Company well to capitalize on substantial growth opportunities across the globe. I stand ready to support the Company’s commitment to high-quality financial reporting and internal control as it navigates through these opportunities in the coming years. I look forward to using my background and skills to facilitate the Company’s growth while we bring increased value to all shareholders.”
Mr. Shea, age 54, has over 30 years of experience in leading and advising financial organizations. Since January 2017, he has operated Woodcliff Advisors LLC, a CPA advisory firm providing counsel to boards, CFOs and senior management. Through Woodcliff, Mr. Shea personally filled CFO roles at public and private companies in the financial services and technology industries. From 1998 to 2016, he was a Senior Vice President at Affiliated Managers Group, Inc., a publicly traded asset management holding company with a long record of growth through acquisition. His core experience is in acquisitions, SEC reporting, internal controls, and the capital markets. Previously, he advised financial services firms at PricewaterhouseCoopers where his clients included asset managers, banks, private equity firms, mutual funds and leasing companies. Mr. Shea is a certified public accountant and earned his B.S. in Finance and Accounting from Boston College.
Mr. Richard T. Schumacher, President and CEO of PBI, added: “We are pleased to have someone with Dan’s experience and capabilities join PBI at such an important time in our corporate evolution. We believe all three of our patented technology business platforms have the potential for rapid growth over the next 12-18 months. To that end, we have given guidance that we believe total revenue in 2020 will be more than double total revenue of 2019. Such rapid growth will require reliable and supportive financial systems to be securely in place to facilitate smooth and timely financial reporting. It will also require a close and continued relationship with the capital markets. We are fortunate to have a seasoned financial professional like Dan join us at this most important time, to lead this financial transformation.”
Mr. Schumacher continued: “I will be transferring many responsibilities to Dan that have been on my plate as interim CFO. This welcomed transition will allow me to focus time on multiple opportunities that we believe offer great potential for commercial growth and increased financial security for PBI, including strategic partnerships, collaborations, acquisitions, and customer adoption/revenue acceleration programs. This is a very exciting time for stakeholders in PBI.”
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. (PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired, patented technology from BaroFold, Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., CBD Oil and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.
(0)
(0)Pressure Biosciences (PBIO) Stock Research Links
What I post is my opinion. Do your own DD. Make your own investment decision. Links, images, & retweets are not endorsements.
1️⃣I do not provide personal investment advice and I am not a qualified licensed investment advisor. I am an amateur investor.
2️⃣All information found here, including any ideas, opinions, views, predictions, forecasts, commentaries, suggestions, or stock picks, expressed or implied herein, are for informational, entertainment or educational purposes only and should not be construed as personal investment advice. While the information provided is believed to be accurate, it may include errors or inaccuracies.
3️⃣I will not and cannot be held liable for any actions you take as a result of anything you read here.
4️⃣Conduct your own due diligence, or consult a licensed financial advisor or broker before making any and all investment decisions. Any investments, trades, speculations, or decisions made on the basis of any information found on this site, expressed or implied herein, are committed at your own risk, financial or otherwise.
1️⃣I do not provide personal investment advice and I am not a qualified licensed investment advisor. I am an amateur investor.
2️⃣All information found here, including any ideas, opinions, views, predictions, forecasts, commentaries, suggestions, or stock picks, expressed or implied herein, are for informational, entertainment or educational purposes only and should not be construed as personal investment advice. While the information provided is believed to be accurate, it may include errors or inaccuracies.
3️⃣I will not and cannot be held liable for any actions you take as a result of anything you read here.
4️⃣Conduct your own due diligence, or consult a licensed financial advisor or broker before making any and all investment decisions. Any investments, trades, speculations, or decisions made on the basis of any information found on this site, expressed or implied herein, are committed at your own risk, financial or otherwise.
Scroll down for more posts ▼